Business Description
Neurizon Therapeutics Ltd
NAICS : 325412
SIC : 2834
ISIN : AU0000357261
Description
Neurizon Therapeutics Ltd is a clinical-stage biotech company that develops drug discovery intellectual property for the treatment of different types of neurodegenerative diseases. Its product pipeline is NUZ-001 (S-Monepantel).
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.92 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -81.7 | |||||
| 3-Year EPS without NRI Growth Rate | -58.7 | |||||
| 3-Year FCF Growth Rate | -67.1 | |||||
| 3-Year Book Growth Rate | -6.3 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 67.29 | |||||
| 9-Day RSI | 68.88 | |||||
| 14-Day RSI | 67.7 | |||||
| 6-1 Month Momentum % | -26.88 | |||||
| 12-1 Month Momentum % | 225 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 12.42 | |||||
| Quick Ratio | 12.42 | |||||
| Cash Ratio | 10.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12 | |||||
| Shareholder Yield % | -12.83 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -106.67 | |||||
| ROA % | -88.73 | |||||
| ROIC % | -271.69 | |||||
| 3-Year ROIIC % | 56.96 | |||||
| ROC (Joel Greenblatt) % | -3849.13 | |||||
| ROCE % | -88.89 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 9.13 | |||||
| Price-to-Tangible-Book | 13.3 | |||||
| EV-to-EBIT | -15.1 | |||||
| EV-to-EBITDA | -15.1 | |||||
| EV-to-FCF | -19.45 | |||||
| Price-to-Net-Current-Asset-Value | 13.3 | |||||
| Price-to-Net-Cash | 13.3 | |||||
| Earnings Yield (Greenblatt) % | -6.62 | |||||
| FCF Yield % | -5.06 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Neurizon Therapeutics Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.013 | ||
| Beta | 1.84 | ||
| Volatility % | 129.63 | ||
| 14-Day RSI | 67.7 | ||
| 14-Day ATR (€) | 0.00224 | ||
| 20-Day SMA (€) | 0.125 | ||
| 12-1 Month Momentum % | 225 | ||
| 52-Week Range (€) | 0.036 - 0.252 | ||
| Shares Outstanding (Mil) | 486.63 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Neurizon Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Neurizon Therapeutics Ltd Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Neurizon Therapeutics Ltd Frequently Asked Questions
What is Neurizon Therapeutics Ltd(STU:ECQ0)'s stock price today?
The current price of STU:ECQ0 is €0.13. The 52 week high of STU:ECQ0 is €0.25 and 52 week low is €0.04.
When is next earnings date of Neurizon Therapeutics Ltd(STU:ECQ0)?
The next earnings date of Neurizon Therapeutics Ltd(STU:ECQ0) is .
Does Neurizon Therapeutics Ltd(STU:ECQ0) pay dividends? If so, how much?
Neurizon Therapeutics Ltd(STU:ECQ0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers